APOBEC3A and breast carcinoma: However, despite extensive research, conflicting results have been reported, with almost half of the studies being negative,14, 19, 20, 21, 22, 23 while conclusions from several meta‐analyses support an increased breast cancer risk in women carrying the APOBEC3A/B deletion variant.22, 33, 34